Propionic Acid

Propionic Acid

SCHEMBL4157712

CCC(=O)O.Nc1nccc(-c2ccc3[nH]c(=O)c4[nH]ccc4c3c2)n1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.41
ROCK1 Q13464 3/20 0.41
AURKA O14965 1/20 0.41
CHUK O15111 1/20 0.41
PDPK1 O15530 1/20 0.41
RPS6KB1 P23443 1/20 0.41
KDR P35968 1/20 0.41
TGFBR1 P36897 1/20 0.41
SYK P43405 1/20 0.41
JAK3 P52333 1/20 0.41
AURKB Q96GD4 1/20 0.41
MAP3K5 Q99683 1/20 0.41
ROCK2 O75116 3/20 0.40
PIM1 P11309 5/20 0.39
PIM3 Q86V86 3/20 0.39
PIM2 Q9P1W9 3/20 0.39
KMO O15229 1/20 0.39
JAK2 O60674 3/20 0.39
CDC7 O00311 3/20 0.39
GSK3B P49841 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL4159507 0.87 PDPK1 (0.42) PDPK1PIM1PIM3PIM2KMO
Propionic Acid SCHEMBL4169954 0.86 AURKA (0.43) AURKAPDPK1SYKAURKBJAK2
Propionic Acid SCHEMBL4160185 0.85 PDPK1 (0.47) CDK2AURKAPDPK1AURKBPIM1
Propionic Acid SCHEMBL4161183 0.83 JAK2 (0.47) SYKJAK3JAK2CDC7GSK3B
Propionic Acid SCHEMBL4160216 0.83 AURKA (0.41) AURKAPDPK1SYKAURKBJAK2
Propionic Acid SCHEMBL4162600 0.83 PARP1 (0.38) PIM1PIM2GSK3B
Propionic Acid SCHEMBL4155444 0.83 PARP1 (0.43) AURKBROCK2PIM1GSK3B
Propionic Acid SCHEMBL4159389 0.82 PIM1 (0.37) PDPK1SYKPIM1PIM3PIM2
Propionic Acid SCHEMBL4153840 0.81 PIM1 (0.44) PIM1GSK3B
Propionic Acid SCHEMBL4159539 0.80 MAPT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 CDK2 28/4885ROCK1 369/4885AURKA 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.